• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Macular Oedema - Pipeline Review, Q4 2010 - Product Image

Macular Oedema - Pipeline Review, Q4 2010

  • ID: 1464265
  • December 2010
  • 30 pages
  • Global Markets Direct

Macular Oedema - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Macular Oedema Pipeline Review, Q4 2010”, provides an overview of the Macular Oedema therapeutic pipeline. This report provides information on the therapeutic development for Macular Oedema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Oedema. “Macular Oedema-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Macular Oedema.
- A review of the Macular Oedema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Macular Oedema Overview
Therapeutics Development
An Overview of Pipeline Products for Macular Oedema
Macular Oedema Therapeutics under Development by Companies
Macular Oedema Therapeutics under Investigation by Universities/Institutes
Companies Involved in Macular Oedema Therapeutics Development
Alcon, Inc.
Allergan, Inc.
National Eye Institute
Inotek Pharmaceuticals Corporation
Alimera Sciences, Inc.
Universities/Institutes Involved in Macular Oedema Therapeutics Development
Macular Oedema Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Nevanac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Interferon beta + Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triamcinolone Acetonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Macular Oedema - Featured News
Jun 22, 2010: Genentech Receives FDA Approval For Lucentis For Treatment Of Macular Edema Following Retinal Vein Occlusion
May 21, 2010: Allergan expected to launch Ozurdex in Europe in Q3
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos